Dr. Arnedos on Next Steps Following the POP Randomized Trial in Breast Cancer

Monica Arnedos, MD
Published: Friday, Oct 14, 2016



Monica Arnedos, MD, assistant professor, Department of Medical Oncology, Institut de Cancérologie Gustave Roussy, shares some of her thoughts regarding next steps following the Preoperative Palbociclib (POP) Randomized Trial for early-stage breast cancer.

The trial aimed to determine whether short-term palbociclib (Ibrance) in the neoadjuvant setting would lead to decreased proliferation and early biomarker changes in patients with early-stage breast cancer.

Next steps, according to Arnedos, will include a closer look at the gene expression in order to determine why some patients in the study did not seem to respond with the same efficacy as others.


Monica Arnedos, MD, assistant professor, Department of Medical Oncology, Institut de Cancérologie Gustave Roussy, shares some of her thoughts regarding next steps following the Preoperative Palbociclib (POP) Randomized Trial for early-stage breast cancer.

The trial aimed to determine whether short-term palbociclib (Ibrance) in the neoadjuvant setting would lead to decreased proliferation and early biomarker changes in patients with early-stage breast cancer.

Next steps, according to Arnedos, will include a closer look at the gene expression in order to determine why some patients in the study did not seem to respond with the same efficacy as others.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x